A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and hydrochlorothiazide in Essential Hypertension, sponsored by Takeda. Completed at 53 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-07.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 9th largest by enrollment, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 6th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2009.
This study's enrollment of 609 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 10th largest by enrollment, is one of 3 that started in 2009, is one of 12 in phase 3, and was the 6th registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the antihypertensive effect of chlorthalidone vs hydrochlorothiazide when each is used with azilsartan medoxomil, once daily (QD), in participants with moderate to severe essential hypertension.
According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.
Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker being evaluated by Takeda to treat essential hypertension.
Treatments for essential hypertension commonly include use of a thiazide-like diuretic, either alone or as part of combination treatment. Although chlorthalidone was commonly prescribed in the past, its use has widely been replaced with hydrochlorothiazide, presumably due to a lack of available combination products containing chlorthalidone, the assumption that hydrochlorothiazide and chlorthalidone have similar antihypertensive effects and cardiovascular benefits, and the perception that chlorthalidone use is associated with a greater frequency of hypokalemia. However, the frequency of hypokalemia with chlorthalidone use is relatively low in the dose range of 12.5 to 25 mg and these doses have been shown to be associated with potent blood pressure reduction. Several long-term outcomes trials have shown that blood pressure reductions associated with chlorthalidone treatment reduce risk of cardiovascular morbidity and mortality.
Most hypertensive patients require two or more agents to achieve target blood pressure and diuretics are commonly used in combination with other antihypertensive agents. This trial is designed to compare chlorthalidone and hydrochlorothiazide when coadministered with azilsartan medoxomil.
Participants in this study will receive either chlorthalidone or hydrochlorothiazide in combination with azilsartan medoxomil. Total commitment time for this study is about 13 weeks. Participants will be required to wear a blood pressure monitor for three 24 hours periods during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Azilsartan medoxomil and hydrochlorothiazide
Drug pages: Azilsartan medoxomil · Chlorthalidone
Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks. For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment.
Also known as: TAK-491, TAK-491CLD
Drug pages: Azilsartan medoxomil · Hydrochlorothiazide
Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks. For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment.
Also known as: TAK-491, TAK-491CLD
Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure
The change in sitting trough clinic systolic blood pressure measured at each week indicated including final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
The change in sitting trough clinic diastolic blood pressure measured at each week indicated including final visit relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in Mean Trough Systolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.
The change in trough systolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.
The change in trough diastolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in 24-hour mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring
The change in the 12-hour mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline, Week 6 and Week 10.
Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring.
The change in the 12-hour mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
Time frame: Baseline, Week 6 and Week 10.
Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic Blood Pressure Targets, Defined as <140 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <130 mm Hg for Participants With Diabetes or Chronic Kidney Disease
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as \<140mm Hg without diabetes or chronic kidney disease or \<130/mm Hg with diabetes or chronic kidney disease. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
Time frame: Week 2, Week 4, Week 6, Week 8 and Week 10.
Percentage of Participants Who Reached Their Trough, Sitting, Clinic Diastolic Blood Pressure Target, Defined as <90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <80 mm Hg for Participants With Diabetes or Chronic Kidney Disease.
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as \<90 mm Hg for participants without diabetes or chronic kidney disease or \<80 mm Hg for participants with diabetes or chronic kidney disease. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.
Time frame: Week 2, Week 4, Week 6, Week 8 and Week 10.
Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic and Diastolic Blood Pressure Targets, Defined as <140/90 mm Hg Without Diabetes or Chronic Kidney Disease or <130/80 mm Hg With Diabetes or Chronic Kidney Disease
Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at each week indicated, defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease or \<130/80 mm Hg for participants with diabetes or chronic kidney disease\[GFR \<60 mL/min/1.73 m2 or urinary albumin:creatinine ratio (UACR) \>200 mg albumin/g creatinine at Screening.\] Systolic/diastolic blood pressure is the average of the 3 serial trough sitting systolic/diastolic blood pressure measurements.
Time frame: Week 2, Week 4, Week 6, Week 8 and Week 10.
Participants enrolled at 66 investigative sites in the Russian Federation and the United States from 20 January 2009 to 30 November 2009.
| Milestone | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Started | 303 | 306 |
| Completed | 252 | 260 |
| Not completed | 51 | 46 |
| Withdrew: Adverse event | 28 | 19 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Withdrawal by subject | 16 | 14 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Other | 2 | 7 |
The change in sitting trough clinic systolic blood pressure measured at each week indicated including final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=295; n=292) | -35.1 ± 0.97 | -29.5 ± 0.98 |
| Week 10 (n=295; n=292) | -37.8 ± 0.91 | -32.8 ± 0.91 |
The change in sitting trough clinic diastolic blood pressure measured at each week indicated including final visit relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=295; n=292) | -15.0 ± 0.55 | -11.2 ± 0.55 |
| Week 10 (n=295; n=292) | -16.4 ± 0.50 | -13.7 ± 0.51 |
The change in trough systolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179, n=162) | -25.7 ± 1.11 | -18.4 ± 1.16 |
| Week 10 (n=227, n=230) | -25.6 ± 0.91 | -21.4 ± 0.90 |
The change in trough diastolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -15.2 ± 0.70 | -10.6 ± 0.74 |
| Week 10 (n=227; n=230) | -15.1 ± 0.63 | -12.7 ± 0.62 |
The change in 24-hour mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179, n=162) | -25.7 ± 0.92 | -19.9 ± 0.97 |
| Week 10 (n=227, n=230) | -26.6 ± 0.80 | -22.4 ± 0.79 |
The change in 24-hour mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -14.7 ± 0.59 | -10.9 ± 0.62 |
| Week 10 (n=227; n=230) | -15.2 ± 0.53 | -12.6 ± 0.53 |
The change in daytime (6am to 10pm) mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -27.0 ± 0.95 | -20.2 ± 1.00 |
| Week 10 (n=227; n=230) | -27.5 ± 0.82 | -22.8 ± 0.82 |
The change in daytime (6am to 10pm) mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -15.4 ± 0.62 | -11.1 ± 0.65 |
| Week 10 (n=227; n=230) | -15.8 ± 0.55 | -12.9 ± 0.55 |
The change in nighttime (12am to 6am) mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -21.8 ± 0.98 | -18.8 ± 1.03 |
| Week 10 (n=227; n=230) | -23.8 ± 0.87 | -21.1 ± 0.87 |
The change in nighttime (12am to 6am) mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -12.8 ± 0.64 | -10.3 ± 0.67 |
| Week 10 (n=227; n=230) | -13.8 ± 0.60 | -11.9 ± 0.60 |
The change in the 12-hour mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -27.7 ± 0.99 | -20.6 ± 1.04 |
| Week 10 (n=227; n=230) | -28.0 ± 0.86 | -23.2 ± 0.86 |
The change in the 12-hour mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.
| mmHg | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 6 (n=179; n=162) | -15.7 ± 0.65 | -11.1 ± 0.68 |
| Week 10 (n=227; n=230) | -16.0 ± 0.59 | -12.9 ± 0.58 |
Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as \<140mm Hg without diabetes or chronic kidney disease or \<130/mm Hg with diabetes or chronic kidney disease. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 2 (n=283; n=276) | 33.2 | 34.1 |
| Week 4 (n=292; n=289) | 68.2 | 54.7 |
| Week 6 (n=295; n=292) | 71.9 | 58.2 |
| Week 8 (n=295; n=292) | 79.7 | 65.4 |
| Week 10 (n=295; n=292) | 76.9 | 69.9 |
Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as \<90 mm Hg for participants without diabetes or chronic kidney disease or \<80 mm Hg for participants with diabetes or chronic kidney disease. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 2 (n=283; n=276) | 49.1 | 41.3 |
| Week 4 (n=292; n=289) | 71.9 | 57.4 |
| Week 6 (n=295; n=292) | 76.6 | 59.2 |
| Week 8 (n=295; n=292) | 81.4 | 72.3 |
| Week 10 (n=295; n=292) | 82.7 | 75.0 |
Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at each week indicated, defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease or \<130/80 mm Hg for participants with diabetes or chronic kidney disease\[GFR \<60 mL/min/1.73 m2 or urinary albumin:creatinine ratio (UACR) \>200 mg albumin/g creatinine at Screening.\] Systolic/diastolic blood pressure is the average of the 3 serial trough sitting systolic/diastolic blood pressure measurements.
| percentage of participants | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Week 2 (n=283; n=276) | 27.2 | 24.6 |
| Week 4 (n=292; n=289) | 58.6 | 45.3 |
| Week 6 (n=295; n=292) | 64.1 | 45.9 |
| Week 8 (n=295; n=292) | 72.5 | 59.2 |
| Week 10 (n=295; n=292) | 71.5 | 62.3 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | — | 6/302 (2%) | 79/302 (26.2%) |
| Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | — | 5/303 (1.7%) | 68/303 (22.4%) |
| Event | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Angina unstableCardiac disorders | 1/302 | 0/303 |
| Coronary artery occlusionCardiac disorders | 1/302 | 0/303 |
| Coronary artery stenosisCardiac disorders | 1/302 | 0/303 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/302 | 0/303 |
| Sudden deathGeneral disorders | 1/302 | 1/303 |
| Chest discomfortGeneral disorders | 1/302 | 0/303 |
| Blood creatinine increasedInvestigations | 1/302 | 0/303 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/302 | 0/303 |
| Renal failure chronicRenal and urinary disorders | 1/302 | 0/303 |
| Chest painGeneral disorders | 0/302 | 1/303 |
| Event | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD |
|---|---|---|
| Blood creatinine increasedInvestigations | 38/302 | 27/303 |
| DizzinessNervous system disorders | 37/302 | 32/303 |
| HeadacheNervous system disorders | 16/302 | 16/303 |
| Age Continuous(years) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| Mean | 56.8 ± 10.79 | 55.9 ± 10.97 | 56.4 ± 10.88 |
| Age, Customized(participants) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| <45 years | 43 | 50 | 93 |
| Between 45 and 64 years | 189 | 195 | 384 |
| ≥65 years | 71 | 61 | 132 |
| Sex: Female, Male(Participants) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| Female | 158 | 155 | 313 |
| Male | 145 | 151 | 296 |
| Ethnicity (NIH/OMB)(Participants) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 28 | 68 |
| Not Hispanic or Latino | 173 | 184 | 357 |
| Unknown or Not Reported | 90 | 94 | 184 |
| Race (NIH/OMB)(participants) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 6 | 1 | 7 |
| Asian | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 46 | 38 | 84 |
| White | 252 | 265 | 517 |
| More than one race | 5 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| United States | 213 | 214 | 427 |
| Russian Federation | 90 | 92 | 182 |
| Estimated glomerular filtration rate (eGFR)(participants) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| Moderate impairment | 23 | 24 | 47 |
| Mild impairment | 180 | 184 | 364 |
| Normal | 100 | 98 | 198 |
| Weight(kg) | Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD | Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD | Total |
|---|---|---|---|
| Mean | 87.60 ± 19.181 | 90.61 ± 19.252 | 89.11 ± 19.260 |
4 further baseline measures are reported on the registry.
The record gives a start of Feb 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone · Hydrochlorothiazide